DK1436427T3 - Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons - Google Patents

Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons

Info

Publication number
DK1436427T3
DK1436427T3 DK02782887T DK02782887T DK1436427T3 DK 1436427 T3 DK1436427 T3 DK 1436427T3 DK 02782887 T DK02782887 T DK 02782887T DK 02782887 T DK02782887 T DK 02782887T DK 1436427 T3 DK1436427 T3 DK 1436427T3
Authority
DK
Denmark
Prior art keywords
composition
antibody treatment
treatment response
response
assessing antibody
Prior art date
Application number
DK02782887T
Other languages
Danish (da)
English (en)
Inventor
Herve Watier
Guillaume Cartron
Philippe Colombat
Original Assignee
Chru Tours
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1436427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chru Tours, Innate Pharma filed Critical Chru Tours
Application granted granted Critical
Publication of DK1436427T3 publication Critical patent/DK1436427T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02782887T 2001-10-19 2002-10-11 Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons DK1436427T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402718 2001-10-19
PCT/EP2002/011397 WO2003035904A2 (fr) 2001-10-19 2002-10-11 Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps

Publications (1)

Publication Number Publication Date
DK1436427T3 true DK1436427T3 (da) 2008-12-08

Family

ID=8182931

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02782887T DK1436427T3 (da) 2001-10-19 2002-10-11 Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons

Country Status (11)

Country Link
US (3) US7858300B2 (fr)
EP (1) EP1436427B1 (fr)
JP (1) JP4216720B2 (fr)
CN (1) CN1329524C (fr)
AT (1) ATE403750T1 (fr)
AU (1) AU2002346999B2 (fr)
CA (1) CA2463746C (fr)
DE (2) DE60228108D1 (fr)
DK (1) DK1436427T3 (fr)
ES (1) ES2311634T3 (fr)
WO (1) WO2003035904A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463746C (fr) 2001-10-19 2014-09-02 Centre Hospitalier Regional Et Universitaire De Tours Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
WO2004011625A2 (fr) * 2002-07-31 2004-02-05 University Of Southern California Polymorphismes de prediction de maladies et resultat therapeutique
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
GB0324778D0 (en) * 2003-10-23 2003-11-26 Forinnova As Method
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
CN1976942A (zh) * 2004-04-07 2007-06-06 希龙公司 用于鉴定fc受体多态性的核酸分析方法
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法
WO2005123947A1 (fr) * 2004-06-15 2005-12-29 Universite Francois Rabelais Procede d'evaluation de la susceptibilite a la thrombocytopenie medicamenteuse
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
AU2005267148A1 (en) * 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
EP1945260B1 (fr) * 2005-11-01 2012-10-24 Novartis AG Utilisations d'anticorps anti-cd40
WO2007053661A2 (fr) * 2005-11-01 2007-05-10 Novartis Ag Utilisations d'anticorps anti-cd40
US20090181016A1 (en) * 2005-11-30 2009-07-16 University Of Southern California FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
CA2650730A1 (fr) * 2006-04-27 2007-11-08 Pikamab, Inc. Procedes et compositions pour la therapie par anticorps
EP2109686A2 (fr) * 2007-01-18 2009-10-21 University Of Southern California Marqueurs genetiques pour la prediction de sensibilite a une polytherapie
US20090142763A1 (en) * 2007-08-22 2009-06-04 Wyeth Nested pcr-based method for specific genotyping of the fc gamma receptor iiia gene
WO2010138725A1 (fr) * 2009-05-28 2010-12-02 Amgen Inc. Traitement du cancer du pancréas à l'aide d'un agoniste dr5 en combinaison avec gemcitabine
EP2383572A1 (fr) * 2010-04-28 2011-11-02 Assistance Publique Hôpitaux de Marseille Test de l'activité humorale cellulaire (CHAT)
RU2441023C1 (ru) * 2010-07-15 2012-01-27 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
FR3037340A1 (fr) * 2015-06-09 2016-12-16 Univ Montpellier Methode de pronostic d'hemopathies lymphoides
EP3356561B1 (fr) * 2015-10-02 2021-10-27 Momenta Pharmaceuticals, Inc. Procédés thérapeutiques et diagnostiques pour des maladies autoimmunes et/ou des inflammations
US10226088B1 (en) * 2017-03-30 2019-03-12 Robert Russell Pet waste disposable glove
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
CN108676875B (zh) * 2018-04-10 2022-01-18 哈尔滨医科大学 Cd20、fcgriia及fcgriiia基因在弥漫大b细胞淋巴瘤预后中的用途
EP3911340A4 (fr) * 2019-01-18 2022-11-16 Acepodia Biotechnologies Ltd. <sup2/>? <sub2/>?+? ?nouvelle cellule tueuse naturelle cd16et procédé de culture de cellule tueuse naturelle cd16 <ns2:sup>+</ns2:sup>
WO2021146521A1 (fr) * 2020-01-16 2021-07-22 Acepodia Biotechnologies Ltd. Nouvelle cellule tueuse naturelle cd16+ et procédé de culture de cellule tueuse naturelle cd16+
CN114277149B (zh) * 2021-12-30 2023-09-22 苏州方科生物科技有限公司 一种检测cd16a基因多态性的试剂盒及其应用和使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446314A (en) * 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Fractionation of heparin
ATE321134T1 (de) * 1988-05-27 2006-04-15 Applied Research Systems Menschlicher fc-gamma-rezeptor iii
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5552526A (en) * 1993-05-14 1996-09-03 Cancer Institute MDC proteins and DNAS encoding the same
US5830652A (en) * 1994-08-30 1998-11-03 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for determining predisposition to severe forms of autoimmune disease by determining Fcy receptor allelic patterns
US5866337A (en) * 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
WO1997046715A1 (fr) * 1996-06-03 1997-12-11 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Polymorphisme du recepteur fc
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
GB9919194D0 (en) 1999-08-14 1999-10-20 Univ Leeds Genetic marker for rheumatoid arthritis
EP1130122A3 (fr) * 2000-02-17 2001-10-17 AstraZeneca AB Méthode de diagnostic des polymorphismes du gène humain EP1-R
CA2463746C (fr) * 2001-10-19 2014-09-02 Centre Hospitalier Regional Et Universitaire De Tours Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
WO2005123947A1 (fr) * 2004-06-15 2005-12-29 Universite Francois Rabelais Procede d'evaluation de la susceptibilite a la thrombocytopenie medicamenteuse

Also Published As

Publication number Publication date
US7858300B2 (en) 2010-12-28
DE60228108D1 (de) 2008-09-18
WO2003035904A2 (fr) 2003-05-01
AU2002346999B2 (en) 2007-11-08
US20110123996A1 (en) 2011-05-26
DE02782887T1 (de) 2005-01-13
ATE403750T1 (de) 2008-08-15
CN1329524C (zh) 2007-08-01
CA2463746C (fr) 2014-09-02
EP1436427A2 (fr) 2004-07-14
CN1571850A (zh) 2005-01-26
EP1436427B1 (fr) 2008-08-06
US20150017633A1 (en) 2015-01-15
WO2003035904A3 (fr) 2003-10-16
JP2005506093A (ja) 2005-03-03
US20050064417A1 (en) 2005-03-24
CA2463746A1 (fr) 2003-05-01
ES2311634T3 (es) 2009-02-16
JP4216720B2 (ja) 2009-01-28

Similar Documents

Publication Publication Date Title
DE60228108D1 (de) Methoden und kompositionen zur bewertung von antikörper behandlungen
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
EP1489968A4 (fr) Analyses pour le suivi des patients atteints du cancer sur la base des taux de constituants d&#39;analyte du systeme des activateurs du plasminogene dans des echantillons de fluide corporel
MX364874B (es) Anticuerpos de il-6 y uso de los mismos.
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
CY1108630T1 (el) Εξεταση βιοισοδυναμιας δια συνθεσεις οι οποιες περιεχουν σιδηρο
NO20081847L (no) Fremgangsmate for a forbedre kognitiv funksjon
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
WO2009043848A3 (fr) Utilisation de l&#39;analyse sérologique du stimulateur de lymphocyte b de cytokine (blys) pour le diagnostic, le pronostic et le criblage de l&#39;efficacité thérapeutique dans des maladies liées à l&#39;immunité, y compris des maladies auto-immunes spécifiques à des organes et des réactions de transfusion
Simpson et al. Periodontal treatment causes a longitudinal increase in nitrite‐producing bacteria
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
DE602004029156D1 (de) Prognose des verlaufs einer krebserkrankung
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
AU2003225900A1 (en) Antibody disulfide isomers, use thereof, and methods of analyzing same
EP1465911A4 (fr) Compositions et methodes concernant le diagnostic et le traitement du diabete, de la resistance a l&#39;insuline et de la dyslipidemie
WO2004034994A3 (fr) Procedes et compositions pour determiner les risques de toxicite d&#39;un traitement
NO20033401D0 (no) Kjemiske forbindelser
WO2003084480A3 (fr) Interaction hausp-p53 et utilisations correspondantes
TW200505461A (en) Moldulation of ATP production or content in the hypothalamus
WO2024263528A3 (fr) Biomarqueurs protéomiques pour prédire une thromboembolie veineuse associée au cancer
EP1489096A4 (fr) Nouvel hemepeptide
MX2008013437A (es) Metodo para administrar tolperisona.